PC3I News
Click here to register. Open to Penn Affiliates.
Actionable mutations are present in 30% of patients with metastatic non-squamous (mNSq) non-small cell lung cancer (NSCLC) where administration of targeted therapy is associated with an overall survival benefit. Guidelines now recommend broad genomic profiling for newly diagnosed mNSq NSCLC patients, however several studies suggest that this is not routinely performed. Penn has successfully implemented “reflex” tissue-based next-generation sequencing (NGS) for mNSq NSCLC at the Hospital of the University of Pennsylvania (HUP). In a recent study, Dr. Aggarwal and colleagues demonstrated that the addition of plasma NGS to tissue NGS testing nearly doubled the rate of detection for actionable mutations. Dr. Aggarwal will describe a new project which seeks to build on this work by fully integrating plasma-based NGS into clinical pathways at HUP and at community oncology practice sites across the University of Pennsylvania Health System. Since the majority of lung cancer patients are treated in the community, it is critical to develop systems that work at both academic as well as community cancer programs.
Dr. Charu Aggarwal, MD, MPH specializes in the management of patients with lung cancer, with a specific and clinical research focus on the development of novel immunotherapeutic approaches, and the discovery and application of biomarkers to guide therapy and monitor treatment. She serves as the local and national principal investigator for multiple clinical trials focusing on the development of “targeted” immunotherapeutic approaches including cellular therapy and CAR-T for solid tumors. Dr. Aggarwal has led trials evaluating the role of plasma-based next generation sequencing in the management of patients with metastatic lung cancer. Dr. Aggarwal performs patient-centered, scientifically relevant novel immunotherapy clinical trials that will make a tangible impact and advance our understanding of immunotherapy in patients with lung cancer.
Related News
PC3I News
Cancer Service Line & PC3I Select 2024 Innovation Accelerator Project
04.22.2024
The Cancer Service Line (CSL) and the Penn Center for Cancer Care Innovation (PC3I) have announced the selection of the 2024 Penn Cancer Innovation Accelerator project. The chosen project, submitted by Katie Boyk, BS, MHA, will identify solutions to improve cancer care scheduling workflows for patients, clinicians, and staff.
PC3I News
PC3I and Tennessee Oncology’s McKay Institute for Oncology Transformation Unveil New Collaborative Relationship
02.06.2024
PC3I and Tennessee Oncology’s McKay Institute for Oncology Transformation announce an academic-community oncology innovation partnership to improve cancer care delivery.
PC3I News
PC3I Leadership Presents at 2023 AORTIC International Conference on Cancer in Africa
12.05.2023
PC3I Associate Director Surbhi Grover and Deputy Director Katharine Rendle presented research at the 14th AORTIC International Conference on Cancer in Africa, which took place in Dakar, Senegal.